Eric Mueller, MD
Rheumatology · Spokane, WANPI 1912017203
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (56.9%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 30 manufacturers reported payments, led by Gilead at 45.8% of the total. Reporting peaked in 2019 at $7,853 and has fallen 75.3% since, to $1,938 in 2025. Among rheumatology clinicians in WA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 432 payments — averaging $32.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$7K
- Amgen$2K
- AbbVie$2K
- Lilly USA, LLC$855
- Novartis$460
- AstraZeneca$456
- plus $2K from 24 others
Across 369 payments — averaging $8110.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$2.2M
- AbbVie$272K
- Eli Lilly$188K
- Sun Pharmaceutical Industries Inc.$187K
- UCB SA$93K
- Sanofi US Services Inc.$5K
- plus $623 from 1 others
What the payments were for
- Consulting fees$5,32037%
- Travel & lodging$7966%
- Food & beverage$8,08357%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 12 | $6,510 |
| Amgen(2 entities) | 139 | $2,081 |
| AbbVie | 74 | $1,839 |
| Lilly USA, LLC | 34 | $855 |
| Novartis | 32 | $460 |
| AstraZeneca | 23 | $456 |
| Genentech USA, Inc. | 29 | $402 |
| UCB, Inc. | 23 | $392 |
| GSK | 19 | $320 |
| Johnson & Johnson | 8 | $167 |
| Pfizer | 8 | $114 |
| Sanofi | 4 | $108 |
| E.r. Squibb & Sons, L.L.C. | 4 | $57 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $54 |
| Bristol Myers Squibb | 2 | $40 |
| Actelion Pharmaceuticals US, Inc. | 2 | $36 |
| Boehringer Ingelheim | 1 | $31 |
| Ferring Pharmaceuticals Inc. | 2 | $31 |
| Regeneron Healthcare Solutions, Inc. | 2 | $30 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $29 |
| Fresenius Kabi USA, LLC | 1 | $26 |
| Alnylam Pharmaceuticals Inc. | 1 | $26 |
| Sobi, Inc | 1 | $23 |
| Aurinia Pharma U.S., Inc. | 1 | $20 |
| Pharming Healthcare, Inc. | 1 | $19 |
| Zimmer Biomet | 1 | $17 |
| Kyowa Kirin, Inc. | 1 | $15 |
| Inova Diagnostics, Inc. | 1 | $15 |
| Medtronic | 1 | $14 |
| Sandoz | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Otezla$150
How this compares
$14,200 in reported general payments places this provider in the 90th percentile of 157 rheumatology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 72 | $598,044 |
| Enbrel SureclickEtanercept | 62 | $464,188 |
| RinvoqUpadacitinib | 56 | $376,331 |
| Xeljanz XrTofacitinib Citrate | 39 | $247,012 |
| Humira PenAdalimumab | 13 | $165,730 |
| Cosentyx Sensoready PenSecukinumab | 14 | $127,659 |
| EnbrelEtanercept | 13 | $102,625 |
| Enbrel MiniEtanercept | 13 | $97,777 |
| Humira(Cf)Adalimumab | 14 | $95,845 |
| Orencia ClickjectAbatacept | 16 | $86,725 |
| OtezlaApremilast | 11 | $52,501 |
| Hydroxychloroquine Sulfate | 385 | $17,876 |
| MethotrexateMethotrexate Sodium | 480 | $9,706 |
| Mycophenolate Mofetil | 70 | $8,863 |
| Colchicine | 39 | $3,846 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq, Humira(Cf) | $1,839 | $472,17570 claims |
| AmgenEnbrel, Otezla | $2,081 | $155,12624 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 157 rheumatology providers in Washington.
Other rheumatology in Spokane
- Howard KenneySpokane$132K
- Usman AjazSpokane$11K
- Michael CoanSpokane$10K
- Rebecca MunteanSpokane$8K
- Barbara JacobsSpokane$5K
- Penny SatherSpokane$4K
- Jeffrey ButlerSpokane$3K
- Raksha PradhanSpokane$2K
- Sean LasalleSpokane$992
- Lauren JohnsonSpokane$887
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.